BRON was designed to recognize the Negative Regulatory Region (NRR) of Notch1, which is the region where gain-of-function mutations have been reported in 50% of T cell acute lymphoblastic leukemia (T-ALL). This evidence concerns the gene NOTCH1 and T-cell acute lymphoblastic leukemia.